Tyrosine ( DrugBank: Tyrosine )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病3
86肺動脈性肺高血圧症6
111先天性ミオパチー1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03655236
(ClinicalTrials.gov)
February 18, 201918/8/2018PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's DiseaseEarly Parkinson DiseaseDrug: K0706;Other: placeboSun Pharma Advanced Research Company LimitedNULLRecruiting50 YearsN/AAll504Phase 2United States;Hungary;India;Poland;Slovakia;Spain
2NCT02259049
(ClinicalTrials.gov)
October 20143/10/2014The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's DiseaseThe Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's DiseaseBlood PressureDietary Supplement: L-tyrosine;Dietary Supplement: Sugar PillNew York Institute of TechnologyNULLCompleted40 Years84 YearsBoth6Phase 0United States
3NCT01676103
(ClinicalTrials.gov)
September 201228/8/2012The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's DiseaseThe Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's DiseaseParkinson's DiseaseDietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar PillNew York Institute of TechnologyMichael J. Fox Foundation for Parkinson's ResearchCompleted50 Years80 YearsBoth40Phase 1/Phase 2United States

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000001709
2009/02/0116/02/2009Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial HypertensionMultikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension - Multikinase Inhibitor for Pulmonary Arterial Hypertension pulmonary arterial hypertensionadministration of sorafenib, which is the multikinase inhibitor (tyrosine and serine/threonine kinase inhibitor)Medical Education Center, School of Medicine, Keio UniversityNULLPending20years-oldNot applicableMale and Female10Not selectedJapan
2JPRN-UMIN000001578
2008/12/0116/12/2008Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial HypertensionTyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension - Tyrosine Kinase Inhibitor for Pulmonary Arterial Hypertension pulmonary arterial hypertensionadministration of tyrosine kinase inhibitor (imatinib)Medical Education CenterNULL20years-oldNot applicableMale and Female10Not selectedJapan
3EUCTR2005-005569-12-AT
(EUCTR)
11/08/200613/07/2006A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension.A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. pulmonary arterial hypertensionProduct Name: Glivec
Product Code: STI571
INN or Proposed INN: Imatinib
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
Austria;Germany;United Kingdom
4EUCTR2005-005569-12-DE
(EUCTR)
24/05/200627/03/2006A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension.A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. pulmonary arterial hypertensionTrade Name: Glivec 100 mg Hartkapsel
Product Name: Glivec
Product Code: STI571
INN or Proposed INN: Imatinib
Trade Name: Glivec 100 mg Filmtabletten
Product Name: Glivec
Product Code: STI571
INN or Proposed INN: Imatinib
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
60Austria;Germany;United Kingdom
5NCT00477269
(ClinicalTrials.gov)
April 200622/5/2007Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial HypertensionA Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial HypertensionDrug: Imatinib mesylate;Drug: PlaceboNovartis PharmaceuticalsNULLCompleted18 YearsN/AAll59Phase 2/Phase 3United States;Austria;Germany;United Kingdom
6EUCTR2005-005569-12-GB
(EUCTR)
26/01/200602/12/2005A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension.A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. pulmonary arterial hypertensionTrade Name: Glivec
Product Name: Glivec
Product Code: STI571
INN or Proposed INN: Imatinib
Product Code: STI571
INN or Proposed INN: Imatinib
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
60Austria;Germany;United Kingdom

111. 先天性ミオパチー


臨床試験数 : 10 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 9
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02035501
(ClinicalTrials.gov)
January 20142/7/2013Treatment of TNNT1-Myopathy With L-Tyrosine.Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.Nemaline MyopathyDrug: L-Tyrosine;Drug: PlaceboHadassah Medical OrganizationNULLEnrolling by invitationN/A20 YearsBoth10Phase 2Israel